The Difference Between Access on Paper and Access in Practice

Understand why specialty drug access breaks down after coverage is approved and how employers can close the gap between coverage and care.

4 Min read
January 7, 2026

Susan Thomas

Chief Commercial Officer, LucyRx

Best Practices

Pharmacist hands searching pills from pharmacy drawer

Access looks great on paper.

A member is “covered.” The medication is “on formulary.” The network is “in place.”

But if you lead HR, you know what happens next. A specialty medication starts and suddenly there is a prior authorization delay, a surprise out-of-pocket cost, a specialty pharmacy onboarding maze, or a refill that does not happen on time.

That is the gap.

Access on paper is a benefit design.

Access in practice is whether a person can start therapy quickly, afford it, and stay on it without their life turning into a full-time project.

And for employers, that gap is not just frustrating. It is expensive.

Specialty drugs represent over half of pharmacy spend, and for conditions like cancer, time to therapy can mean everything.

Where specialty access breaks down

Specialty care is complex by nature. The problem is that the system often asks the member to act as the coordinator.

The friction shows up in predictable places:

Delays in approval and onboarding. In the AMA’s prior authorization survey, 25% of physicians report prior-auth delays led to a serious adverse event
Administrative barriers that lead to abandonment. Members facing administrative hurdles are 7× more likely to stop treatment
Affordability gaps that appear after therapy begins. Copays, coinsurance, and assistance programs are often discovered too late.
Fragmented coordination. Prescriber, specialty pharmacy, PBM, and member are rarely working from the same playbook.

When those breakdowns happen, the consequences are real. Gaps in treatment, avoidable urgent-care visits, and wasted medication drive total cost up, even when a plan has “good coverage” on paper.

What employers should expect instead

Access in practice means three things happen reliably.

1) Therapy starts faster

Traditional PBM models often route specialty prescriptions through centralized hubs.

LucyRx flips that model.

Through our Connected Specialty Care Network, LucyRx connects members directly to health-system specialty pharmacies embedded within the care setting, with more than 130 partners nationwide.

In published studies of integrated health-system specialty pharmacy models, time to therapy has been reduced by up to 80%.

Faster starts matter because delays create risk.

2) Care stays coordinated with the care team

When specialty dispensing is integrated at the point of care, pharmacists are not operating in a call center. They are part of the care team.

That collaboration is what prevents missed steps, reduces therapy disruptions, and supports better symptom control. Published studies of medically integrated specialty pharmacies show fewer emergency room visits, lower treatment disruption, and better outcomes for patients receiving care through these models.

3) Cost barriers get solved before they derail therapy

Affordability is not a side issue in specialty care. It is the difference between starting and stopping.

LucyRx Care Guides step in early to coordinate:

copay and patient assistance programs
cost-share optimization and test claims
specialty pharmacy onboarding
refill and continuity support

This is high-touch support backed by clinical workflows, designed to remove friction, speed access, and lower cost.

What this looks like in real life

A family managing severe hemophilia had experience navigating specialty therapy, but they were still dealing with missed doses and rising costs when moving between PBMs.

Before the plan even started with LucyRx, a Care Guide stepped in to coordinate a transition to an appropriate hemophilia specialty pharmacy, confirm reliable service, and set up a seamless medication schedule.

The Care Guide also helped eliminate out-of-pocket costs through the LucyRx Copay Assistance program, and secured better pricing through specialty network partners. The result was more than $100,000 in projected annual savings for the plan, and day-one medication stability that reduced the risk of missed doses and avoidable ER visits.

That is access in practice.

What outcomes you can hold us accountable to

Employers should not have to choose between a better member experience and better economics.

LucyRx Care Guides are designed to produce measurable outcomes, including:

$10–$12 PMPM average savings, including impact from biosimilar transitions and specialty drug sourcing
2.5:1 to 3:1 ROI across covered populations
fewer urgent-care visits and fewer gaps in treatment
reduced waste from unused medication

In specialty specifically, integrated health-system dispensing models have shown up to 14% lower oncology prescription costs and 32% lower oncology medical charges compared with nonintegrated models.¹

And the human experience matters, too. Members supported by LucyRx Care Guides report 99% satisfaction, and LucyRx maintains an NPS of 65 among plan sponsors.

The takeaway for HR leaders and brokers

Access on paper is not the finish line.

Access in practice is what’s needed when care gets complicated.

It is therapy that starts faster.

It is fewer disruptions.

It is affordability addressed early.

It is a care team that stays connected.

That is what LucyRx was built to deliver.

If you are evaluating specialty strategies for the year ahead, there is a more useful starting point than discounts or network maps:

Get a specialty performance baseline.

Understand how long therapy actually takes to start today. Where delays occur. Where cost barriers derail treatment. Where employees and HR teams are forced to intervene.

That baseline is how you separate access on paper from access in practice and hold your specialty strategy accountable to real outcomes.

That is the difference between coverage and care.

Understand your specialty access in practice

Coverage does not show where specialty care breaks down.

Tell us about your plan and what you are seeing today, and our team will help assess where delays, cost barriers, or coordination gaps may exist.

Contact Us

The Difference Between Access on Paper and Access in Practice

4 Min read

Susan Thomas

Where specialty access breaks down

What employers should expect instead

1) Therapy starts faster

2) Care stays coordinated with the care team

3) Cost barriers get solved before they derail therapy

What this looks like in real life

What outcomes you can hold us accountable to

The takeaway for HR leaders and brokers

Understand your specialty access in practice

Tags

Recommended Reads

Share

Company

Resources

Connect

Follow us

Download the PBM Reform Readiness Checklist

Download the GLP-1 Planning Checklist